$PLX
Protalix BioTherapeutics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000110465920092375 Filed on August 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $10.97M $12.25M $10.44M
YoY Change -10.45% 510.52% 129.3%
Cost Of Revenue $1.827M $2.695M $2.045M
YoY Change -32.21% 23.45% -30.06%
Gross Profit $9.140M $9.552M $8.390M
YoY Change -4.31% -5496.61% 415.04%
Gross Profit Margin 83.34% 77.99% 80.36%
Selling, General & Admin $2.194M $2.068M $2.230M
YoY Change 6.09% -4.17% -10.73%
% of Gross Profit 24.0% 21.65% 26.58%
Research & Development $9.186M $13.32M $11.70M
YoY Change -31.05% 78.21% 60.6%
% of Gross Profit 100.5% 139.48% 139.46%
Depreciation & Amortization $330.0K $370.0K $405.0K
YoY Change -10.81% -11.9% -5.81%
% of Gross Profit 3.61% 3.87% 4.83%
Operating Expenses $11.38M $15.39M $13.93M
YoY Change -26.06% 59.76% 42.39%
Operating Profit -$2.240M -$5.839M -$5.534M
YoY Change -61.64% -39.02% 7.44%
Interest Expense -$1.910M -$1.900M -$1.730M
YoY Change 0.53% 10.47% -17.22%
% of Operating Profit
Other Income/Expense, Net -$1.910M -$1.904M -$1.730M
YoY Change 0.32% 10.83% -17.15%
Pretax Income -$4.150M -$7.740M -$7.260M
YoY Change -46.38% -8.51% 0.28%
Income Tax
% Of Pretax Income
Net Earnings -$4.150M -$7.743M -$7.264M
YoY Change -46.4% -31.44% 0.35%
Net Earnings / Revenue -37.84% -63.22% -69.58%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$0.52 -$0.49
COMMON SHARES
Basic Shares Outstanding 148.4M 148.4M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.800M $25.10M $30.40M
YoY Change -80.88% -11.31% -26.39%
Cash & Equivalents $4.843M $25.10M $30.36M
Short-Term Investments
Other Short-Term Assets $2.893M $2.200M $1.706M
YoY Change 31.5% -11.96% -34.38%
Inventory $11.07M $7.000M $6.707M
Prepaid Expenses
Receivables $5.262M $7.300M $8.565M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $54.21M $41.60M $47.34M
YoY Change 30.31% -3.37% -14.99%
LONG-TERM ASSETS
Property, Plant & Equipment $4.793M $11.80M $6.058M
YoY Change -59.38% 70.03% -17.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.000M $1.900M $1.800M
YoY Change 268.42% 11.76% 0.0%
Total Long-Term Assets $17.50M $13.60M $13.70M
YoY Change 28.68% 56.88% 50.43%
TOTAL ASSETS
Total Short-Term Assets $54.21M $41.60M $47.34M
Total Long-Term Assets $17.50M $13.60M $13.70M
Total Assets $71.71M $55.20M $61.04M
YoY Change 29.91% 6.73% -5.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.700M $6.700M $5.900M
YoY Change 0.0% 11.67% 20.41%
Accrued Expenses $1.100M $1.200M $1.300M
YoY Change -8.33%
Deferred Revenue $18.35M $9.429M
YoY Change
Short-Term Debt $4.300M $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $42.42M $26.00M $27.04M
YoY Change 63.13% 72.51% 25.75%
LONG-TERM LIABILITIES
Long-Term Debt $52.70M $54.70M $54.00M
YoY Change -3.66% 5.19% 5.26%
Other Long-Term Liabilities $124.0K $42.00M $5.290M
YoY Change -99.7% 698.78% 2.28%
Total Long-Term Liabilities $64.06M $96.70M $93.86M
YoY Change -33.75% 12.15% 13.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.42M $26.00M $27.04M
Total Long-Term Liabilities $64.06M $96.70M $93.86M
Total Liabilities $106.5M $122.7M $120.9M
YoY Change -13.22% 21.13% 15.99%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$34.76M -$67.49M -$59.86M
YoY Change
Total Liabilities & Shareholders Equity $71.71M $55.20M $61.04M
YoY Change 29.91% 6.73% -5.79%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$4.150M -$7.743M -$7.264M
YoY Change -46.4% -31.44% 0.35%
Depreciation, Depletion And Amortization $330.0K $370.0K $405.0K
YoY Change -10.81% -11.9% -5.81%
Cash From Operating Activities -$7.830M -$5.170M -$7.276M
YoY Change 51.45% -35.13% -22.7%
INVESTING ACTIVITIES
Capital Expenditures $210.0K $40.00K $170.0K
YoY Change 425.0% -71.43% -31.73%
Acquisitions
YoY Change
Other Investing Activities -$60.00K -$60.00K -$13.00K
YoY Change 0.0% -300.0% -88.07%
Cash From Investing Activities -$270.0K -$100.0K -$371.0K
YoY Change 170.0% -16.67% 13.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.270M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -7.830M -5.170M -7.276M
Cash From Investing Activities -270.0K -100.0K -371.0K
Cash From Financing Activities -1.270M 0.000
Net Change In Cash -9.370M -5.270M -7.647M
YoY Change 77.8% -58.96% -21.5%
FREE CASH FLOW
Cash From Operating Activities -$7.830M -$5.170M -$7.276M
Capital Expenditures $210.0K $40.00K $170.0K
Free Cash Flow -$8.040M -$5.210M -$7.446M
YoY Change 54.32% -35.76% -22.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Income Loss
NetIncomeLoss
-2483000
dei Entity Central Index Key
EntityCentralIndexKey
0001006281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33357
dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
CY2019Q4 us-gaap Assets
Assets
45392000
CY2020Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6707000
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Snunit Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Science Park
dei Entity Address Address Line3
EntityAddressAddressLine3
POB 455
dei Entity Address City Or Town
EntityAddressCityOrTown
Carmiel
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
2161401
dei City Area Code
CityAreaCode
972-4
dei Local Phone Number
LocalPhoneNumber
988-9488
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
PLX
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32442636
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4843000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17792000
CY2020Q2 plx Short Term Bank Deposits
ShortTermBankDeposits
30147000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5262000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4700000
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2893000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1832000
CY2020Q2 us-gaap Inventory Net
InventoryNet
11065000
CY2019Q4 us-gaap Inventory Net
InventoryNet
8155000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
54210000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
32479000
CY2020Q2 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
5025000
CY2020Q2 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
2005000
CY2019Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1963000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4793000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5273000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5677000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5677000
CY2020Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
17500000
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
12913000
CY2020Q2 us-gaap Assets
Assets
71710000
CY2019Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6495000
CY2020Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
11910000
CY2019Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
11905000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1145000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1139000
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18352000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16335000
CY2020Q2 us-gaap Notes Payable Current
NotesPayableCurrent
4301000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4301000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
42415000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40175000
CY2020Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
52622000
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
50957000
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4122000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
16980000
CY2020Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2665000
CY2019Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2565000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4526000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4528000
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
124000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
509000
CY2020Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
64059000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
75539000
CY2020Q2 us-gaap Liabilities
Liabilities
106474000
CY2019Q4 us-gaap Liabilities
Liabilities
115714000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-34764000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-70322000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71710000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45392000
us-gaap Revenues
Revenues
32613000
us-gaap Revenues
Revenues
22686000
CY2020Q2 us-gaap Revenues
Revenues
10967000
CY2019Q2 us-gaap Revenues
Revenues
12247000
us-gaap Cost Of Revenue
CostOfRevenue
5253000
us-gaap Cost Of Revenue
CostOfRevenue
4740000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
1827000
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
2695000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19526000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25021000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9186000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13323000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5381000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4298000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2194000
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2068000
us-gaap Operating Income Loss
OperatingIncomeLoss
2453000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11373000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2240000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5839000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
5177000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
3827000
CY2020Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1948000
CY2019Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1907000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
241000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
193000
CY2020Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
38000
CY2019Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4936000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3634000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1910000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1904000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-150000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
107000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
13000
us-gaap Net Income Loss
NetIncomeLoss
-15007000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4150000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7743000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.01
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19923935
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14838213
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32442636
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14838213
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-52881000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
403000
us-gaap Net Income Loss
NetIncomeLoss
-15007000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-67485000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-70322000
plx Issuance Of Common Stock And Warrants Net Of Issuance Cost Value
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
41343000
plx Receivables From Sale Of Common Stock And Warrants
ReceivablesFromSaleOfCommonStockAndWarrants
4000000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
698000
us-gaap Net Income Loss
NetIncomeLoss
-2483000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-34764000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-59855000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
113000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7743000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-67485000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-30881000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
267000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4150000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-34764000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
us-gaap Net Income Loss
NetIncomeLoss
-2483000
us-gaap Net Income Loss
NetIncomeLoss
-15007000
us-gaap Share Based Compensation
ShareBasedCompensation
698000
us-gaap Share Based Compensation
ShareBasedCompensation
403000
us-gaap Depreciation
Depreciation
710000
us-gaap Depreciation
Depreciation
784000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
250000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
-22000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1665000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1435000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-10841000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-442000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1621000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2811000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-27000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
69000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2910000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1571000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
309000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1471000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-385000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
56000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14952000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12446000
plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
35000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
278000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
207000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
236000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
69000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
23000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35347000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-466000
plx Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
37343000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37343000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
7000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
200000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12949000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12712000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17792000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37808000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4843000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25096000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
50000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
329000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
362000
plx Note Receivable From Issuance Of Common Stock And Warrants Net Of Issuance Cost
NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
4000000
CY2020Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
41300000
CY2020Q3 us-gaap Proceeds From Sale And Collection Of Receivables
ProceedsFromSaleAndCollectionOfReceivables
4600000
CY2020Q3 plx Total Proceeds From Accounts Receivable Outstanding Chiesi
TotalProceedsFromAccountsReceivableOutstandingChiesi
1600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7812543
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18445764
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7805142
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25997289
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3902000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3607000
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
560000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
552000
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6603000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3996000
CY2020Q2 us-gaap Inventory Net
InventoryNet
11065000
CY2019Q4 us-gaap Inventory Net
InventoryNet
8155000
CY2020Q1 plx Non Refundable Payment
NonRefundablePayment
1000000.0

Files In Submission

Name View Source Status
0001104659-20-092375-index-headers.html Edgar Link pending
0001104659-20-092375-index.html Edgar Link pending
0001104659-20-092375.txt Edgar Link pending
0001104659-20-092375-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20200630.xsd Edgar Link pending
plx-20200630x10q.htm Edgar Link pending
plx-20200630x10q005.jpg Edgar Link pending
plx-20200630x10q006.jpg Edgar Link pending
plx-20200630x10q_htm.xml Edgar Link completed
plx-20200630xex10d1.htm Edgar Link pending
plx-20200630xex31d1.htm Edgar Link pending
plx-20200630xex31d2.htm Edgar Link pending
plx-20200630xex32d1.htm Edgar Link pending
plx-20200630xex32d2.htm Edgar Link pending
plx-20200630xex4d8.htm Edgar Link pending
plx-20200630xex4d9.htm Edgar Link pending
plx-20200630_cal.xml Edgar Link unprocessable
plx-20200630_def.xml Edgar Link unprocessable
plx-20200630_lab.xml Edgar Link unprocessable
plx-20200630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending